Emerald Mutual Fund Advisers Trust’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-255,387
| Closed | -$26M | – | 258 |
|
|
2023
Q2 | $26M | Buy |
255,387
+369
| +0.1% | +$34.9K | 1.41% | 12 |
|
|
2023
Q1 | $23.2M | Sell |
255,018
-271,427
| -52% | -$15.9M | 1.37% | 14 |
|
|
2022
Q4 | $20M | Buy |
526,445
+85,727
| +19% | +$2.95M | 1.24% | 26 |
|
|
2022
Q3 | $11.1M | Buy |
440,718
+189,450
| +75% | +$5.25M | 0.7% | 60 |
|
|
2022
Q2 | $7.64M | Buy |
251,268
+33,262
| +15% | +$992K | 0.44% | 88 |
|
|
2022
Q1 | $7.14M | Buy |
218,006
+43,690
| +25% | +$1.3M | 0.32% | 103 |
|
|
2021
Q4 | $4.6M | Sell |
174,316
-106,500
| -38% | -$8.24M | 0.16% | 131 |
|
|
2021
Q3 | $28.3M | Buy |
280,816
+28,340
| +11% | +$3.32M | 0.98% | 40 |
|
|
2021
Q2 | $35.7M | Buy |
252,476
+979
| +0.4% | +$111K | 1.17% | 22 |
|
|
2021
Q1 | $25.1M | Buy |
+251,497
| New | +$29.3M | 0.83% | 45 |
|
|
2020
Q3 | – | Sell |
-57,635
| Closed | -$8.99M | – | 369 |
|
|
2020
Q2 | $8.99M | Sell |
57,635
-41,739
| -42% | -$6.35M | 0.42% | 82 |
|
|
2020
Q1 | $14.3M | Buy |
99,374
+1,570
| +2% | +$303K | 0.9% | 35 |
|
|
2019
Q4 | $20M | Sell |
97,804
-169,517
| -63% | -$30.9M | 0.82% | 42 |
|
|
2019
Q3 | $21.5M | Sell |
267,321
-92,649
| -26% | -$7.86M | 0.95% | 30 |
|
|
2019
Q2 | $34M | Hold |
359,970
| – | – | 1.35% | 16 |
|
|
2019
Q1 | $30.8M | Sell |
359,970
-126,240
| -26% | -$10.5M | 1.23% | 20 |
|
|
2018
Q4 | $27.3M | Buy |
486,210
+41,718
| +9% | +$2.55M | 1.27% | 11 |
|
|
2018
Q3 | $36.3M | Sell |
444,492
-42,249
| -9% | -$2.98M | 1.23% | 9 |
|
|
2018
Q2 | $17M | Buy |
486,741
+15,627
| +3% | +$476K | 0.62% | 57 |
|
|
2018
Q1 | $9.66M | Buy |
471,114
+11,930
| +3% | +$307K | 0.38% | 104 |
|
|
2017
Q4 | $13M | Sell |
459,184
-13,867
| -3% | -$387K | 0.52% | 66 |
|
|
2017
Q3 | $14.7M | Buy |
473,051
+179,124
| +61% | +$5.39M | 0.61% | 55 |
|
|
2017
Q2 | $9.3M | Buy |
293,927
+19,235
| +7% | +$473K | 0.41% | 91 |
|
|
2017
Q1 | $6.22M | Buy |
274,692
+45,133
| +20% | +$1.11M | 0.28% | 118 |
|
|
2016
Q4 | $5.01M | Buy |
229,559
+119
| +0.1% | +$3.01K | 0.24% | 132 |
|
|
2016
Q3 | $6.05M | Buy |
229,440
+47,050
| +26% | +$934K | 0.31% | 117 |
|
|
2016
Q2 | $3.6M | Buy |
+182,390
| New | +$3.55M | 0.2% | 138 |
|
Other funds holding RETA
Emerald Mutual Fund Advisers Trust's RETA Position: Q3 2023 in Review
Emerald Mutual Fund Advisers Trust sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 255,387 shares — an estimated $26M sold.
Emerald Mutual Fund Advisers Trust first reported a position in RETA in Q2 2016 and held it in 27 quarters. The position peaked at $36.3M in Q3 2018. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Emerald Mutual Fund Advisers Trust reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Emerald Mutual Fund Advisers Trust sold 255,387 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $26M.
- Emerald Mutual Fund Advisers Trust first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 27 quarters.
- Emerald Mutual Fund Advisers Trust's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $36.3M in Q3 2018.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q3 2023, filed 27 Oct 2023.